Biohaven Ltd
BHVN13.935USD
-0.135-0.96%
Fechamento 09/12, 16:00（ET）Cotações atrasadas em 15 min
1.47BValor de mercado
PerdaP/L TTM
Mais detalhes de Biohaven Ltd Empresa
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Informações da empresa
Código da empresaBHVN
Nome da EmpresaBiohaven Ltd
Data de listagemSep 23, 2022
CEODr. Vlad Coric, M.D.
Número de funcionários256
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 23
Endereço215 Church Street
CidadeNEW HAVEN
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal06510
Telefone12034040410
Sitehttps://www.biohaven.com/
Código da empresaBHVN
Data de listagemSep 23, 2022
CEODr. Vlad Coric, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Outro
67.49%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Outro
67.49%
Tipos de investidores
Investidores
Proporção
Investment Advisor
34.60%
Investment Advisor/Hedge Fund
25.54%
Hedge Fund
16.34%
Individual Investor
11.13%
Research Firm
3.52%
Venture Capital
1.11%
Sovereign Wealth Fund
0.85%
Corporation
0.48%
Pension Fund
0.47%
Outro
5.96%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
561
102.09M
99.98%
-11.50M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
T. Rowe Price Associates, Inc.
2.74M
2.69%
-594.84K
-17.82%
Mar 31, 2025
Bellevue Asset Management AG
2.04M
2%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
iShares Neuroscience and Healthcare ETF
3.16%
Roundhill GLP-1 & Weight Loss ETF
1.85%
Global X Guru Index ETF
1.14%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
F/m Emerald Life Sciences Innovation ETF
0.61%
Inspire Small/Mid Cap ESG ETF
0.22%
JPMorgan Fundamental Data Science Small Core ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
BNY Mellon US Small Cap Core Equity ETF
0.07%
Strive Small-Cap ETF
0.05%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção3.16%
Roundhill GLP-1 & Weight Loss ETF
Proporção1.85%
Global X Guru Index ETF
Proporção1.14%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.81%
F/m Emerald Life Sciences Innovation ETF
Proporção0.61%
Inspire Small/Mid Cap ESG ETF
Proporção0.22%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.09%
BNY Mellon US Small Cap Core Equity ETF
Proporção0.07%
Strive Small-Cap ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
